Sex hormone-induction and dietary modulation of prostatic adenocarcinoma (PA) in animal models

Urologic Oncology

Volumn 2, Issue 4, 1996, Pages 110-115

  Ho, Shuk Mei ^a   Lane, Kate ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0006027782     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)82841-4     Document Type: Note

References (59)

1. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int. J Cancer 1982;29:611-66.
2. Carter BS, Carter B, Isaacs JT. Epidemiological evidence regarding predisposing factors to prostate cancer. The Prostate 1990;16:187-97.
3. Giovannucci E. Epidemiologic characteristics of prostate cancer. Cancer 1995;75(suppl):1766-77.
4. Gray A, Berlin JA, McKinlay JR, Longcope C. An examination of research design effects on the association of testosterone and male aging: Results of a meta-analysis. J Clin Epidemiol 1991;44:671-84.
5. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metabol 1991;73:221-4.
6. Kreig M, Nass R, Tunn S. Effect of aging on endogenous level of 5a dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic prostate. J Clin Endocrinol Metab 1993;77:375-81.
7. Zumoff B, Strain GW, Kream J, O'Connor J, Rosenfeld RS, Levin J, Fukushima DK. Age variation of the 24-hour mean plasma concentrations of androgens, estrogens, and gonadotrophins in normal adult men. J Clin Endocrinol Metabol 1982;54:534-8.
8. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;75:45-8.
9. Srinivasan SR, Freedman DS, Sundaram GS, Webber LS, Berenson GS. Racial (Black-white) comparisons of the relationship of levels of endogenous sex hormones to serum lipoproteins during male adolescence: The Bogalusa heart study. Circulation 1986;74:1226-1234.
10. Barret-Connor E, Garland C, McPhilips JB, Khan KT, Wingard DL A prospective population-based study of androstenedione, estrogens and prostate cancer. Cancer Res 50:169-73.
11. Ehara H, Koji T, Deguchi T, Yoshi A, Nakano M, Nakane PK, Kawada Y. Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry. The Prostate 1995;27:304-13.
12. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. A prospective study of dietary fat and risk of prostate cancer [see comment citation in Medline]. J Natl Cancer Inst 1993;85:1571-79.
13. Le Marchand L, Kolonel LN, Wilkens LR, Myers BC, Hirohata T. Animal fat consumption and prostate cancer: A prospective study in Hawaii [see comment citation in Medline]. Epidemiology 1994;5:276-82.
14. Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, The CZ, Stamey T. Family history and prostate cancer risk in black, white and Asian men in the United States and Canada. Am J Epidemiol 1995:141:732-40.
15. Kolonel LN, Hankin JH, Yoshizawa CN. Vitamin A and prostate cancer in elderly men: Enhancement of risk. Cancer Res 1987;47:2982-5.
16. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GZ, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767-76.
17. Cults JH. Estrone-induced mammary tumors in the rat. II. Effects of alterations in the hormonal environment on tumor induction, behavior, and growth. Cancer Res 1963;24:1135-30.
18. Cutts JH, Noble RL. Estrone-induced mammary tumors in the rat. I. Induction and behavior of tumors. Cancer Res 1963;24:1116-23.
19. Noble RL, Clayton Hochachka B, King D. Spontaneous and estrogen-produced tumors in Nb rats and their behavior after transplantation. Cancer Res 1975;35:766-80.
20. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and SpragueDawley Hsd:SD rats treated with a combination of testosterone and estradiol-17b or diethylstilbestrol. Carcinogenesis 1995:16:1311-7.
21. Noble RL. Production of Nb rat carcinoma of the dorsolateral prostate and response of estrogen dependent transplants to sex hormones and tamoxifen. Cancer Res 1980;40:3574-50.
22. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-33.
23. Drago JR. The induction of Nb rat prostatic carcinomas. Anticancer Res 1984;4:255-6.
24. Noble RL. Development of androgen-stimulated transplants of Nb rat carcinoma of the dorsal prostate and their response to sex hormones and tamoxifen. Cancer Res 1980;40:3551-4.
25. Ofner P, Bosland MC, Vena RL. Differential effects of diethylstilbestrol and estradiol-17b in combination with testosterone on rat prostate lobes. Toxicology and Applied Pharmacology 1992;112(2):300-9.
26. Noble RL. Prostate carcinoma of the Noble rat in relation to hormones. Int Rev Exp Path 1982;23:113-59.
27. Drago JR, Ikeda RM, Maurer RE, Goldman LB, Tesluk H. The Nb rat: Prostatic adenocarcinoma model. Invest Urol 1979;16:242-9.
28. Ho S-M, Leav I, Damassa D, Kwan PWL, Merk FB, Seto HSK. Testosterone-mediated increase in 5a-dihydrotestosterone content, nuclear androgen receptor levels, and cell division in an androgen-independent prostate carcinoma of Noble rats. Cancer Res 1988;48:609-14.
29. Leav I, Kwan PWL, Merk FB, Chang C, Ho S-M. Immunohistochemical and in situ hybridization studies of androgen receptor expression in a transplantable androgen independent prostatic carcinoma line (AIT) of Noble rats. Lab Invest 1992;67:788-95.
30. Leav 1, Ho S-M, Ofner P, Merk FB, Kwan PWL, Damassa D. Biochemical alterations in sex hormone induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 1988;80:1045-53.
31. Leav I, Merk FB, Kwan PWL, Ho S-M. Androgen supported estrogen enhanced epithelial proliferation in the prostates of intact Noble rats. The Prostate 1989;15:23-40.
32. Bostwick DG. High grade prostatic intraepithelial neoplasia. Cancer 1995;75:1823-36.
33. Ho S-M, Yu M. Selective increases in type II estrogen binding sites in the dysplastic dorsolateral prostates of Noble rats. Cancer Res 1993;53:528-32.
34. Yu M, Leav BA, Leav I, Merk FB, Wolfe H, Ho S-M. Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17b induced prostatic dysplasia of Noble rats, lab Invest 1993;68:33-44.
35. Kaplan PJ, Leav I, Greenwood J, Kwan PWL, Ho S-M. Involvement of transforming growth factor a (TGFa) and epidermal growth factor receptor (EGPR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. Carcinogenesis 1996; in press.
36. Leav I, Loda M, Magi Galluzzi C, Stork PJS, Ho S-M, Ziar J. MAP-kinase and MAP-kinase phosphatase-1 in the Noble rat model of sex hormone induced prostatic dysplasia and carcinoma. Lab Invest 1996;75:361-70.
37. Ho S-M, Roy D. Sex hormone induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett 1994;84:155-62.
38. Han X, Leihr JG, Bosland MC. Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17b and testosterone. Carcinogenesis 1995;16:951-4.
39. Lane KE, Ricci MJ, Ho S-M. The effect of sex hormone treatments on the metabolism of estradiol (E2) in the prostate and liver of Noble rats. The Prostate 1997; In press.
40. Lane KE, Leav 1, Ziar J, Bridges RS, Rand WS, Ho S-M. Suppression of testosterone and estradiol-17b induced dysplasia in the dorsolateral prostate of Noble rats by bromocriptine but not ICI 182,780. In revision.
41. Pollard M. Spontaneous prostate adenocarcinomas in aged germ-free Wistar rats. J Natl Cancer Inst 1973;51:1235-41.
42. Pollard M, Luckert PH, Schmidt MA. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. The Prostate 1982;3:563-8.
43. Pollard M, Snyder DL, Luckert PH. Dihydrotestosterone does not induce prostate adenocarcinoma in L-W rats. The Prostate 1987;10:325-31.
44. Pollard M, Luckert PH, Snyder DL. Prevention and treatment of experimental prostate cancer in Lobund-Wistar Rats. 1. Effects of estradiol, dihydrotestosterone and castration. The Prostate 1989;15:95-103.
45. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by 4-hydroxyphenylretinamide. Cancer Res 1991;51:3610-6.
46. Pollard M, Luckert PH. Promotional effects of testosterone and high fat diet on the development of autochthonous prostate cancer in rats. Cancer Lett 1986;32:223-7.
47. Pollard M, Luckert PH, Snyder DL. Prevention of prostate cancer and liver tumors in L-W rats by moderate dietary restriction. Cancer 1989;64:686-90.
48. Pollard M, Luckert PH, Snyder DL. The promotional effect of testosterone on induction of prostate cancer in MNUsensitized L-W rats. Cancer Lett 1989:45:209-12.
49. Cohen MB, Heidger PM, Lubaroff DM. Gross and microscopic pathology of induced prostatic complex tumors arising in Lobund-Wistar rats. Cancer Res 1994;54:626-8.
50. Pollard M, Luckert P. Autochthonous prostate adenocarcinoma in Lobund-Wistar rats: A model system. The Prostate 1987:11:219-27.
51. Pugh TD, Chang C, Uemura H, Weindruch R. Prostatic localization of spontaneous early invasive carcinoma in LobundWistar rats. Cancer Res 1994;54:5766-70.
52. Chang CF, Pollard M. In vitro propagation of prostate adenocarcinoma cells from rats. Invest Urol 1977;14:331-4.
53. Pollard M, Luckert PH. Patterns of spontaneous metastasis manifested by three rat prostate adenocarcinomas. J Surg Oncol 1979;12:371-7.
54. Pollard M, Chang CF, Luckert PH. Investigations on prostate adenocarcinomas in rats. Oncology 1977:34:129-32.
55. Pollard M, Luckert P. The beneficial effects of diphosphonate and piroxicam on the osteolytic spread of rat prostate carcinoma cells. The Prostate 1986;8:81-6.
56. Pollard M, Luckert PH. In vivo model systems for assessing an anti-cancer drug: Responses of autochthonous and transplanted prostate tumors to cyclophosphamide. Anticancer Res 1990;10:33-6.
57. Pollard M, Burleson GH, Luckert PH. Interference with in vivo growth and metastasis of prostate adenocarcinoma (PAIII) by ICRF-159. The Prostate 1981;2:1-10.
58. Neubauer BL, Bemis KG, Best KL, Goode RL, Hoover DM, Smith GF, Tanzer LR, Merriman RL. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat. JUrol 1986;135:163-6.
59. Neubauer BL, Best KL, Goode RL, Heiman ML, Hoover DM, Robertson DW, Sarosdy MF, Shaar CJ, Tanzer LR, Merriman RL. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma. Cancer Res 1992:52:4663-71.